Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

Posted: January 13, 2025 at 2:54 am

-- One year after the second vaccine dose, the anti-gE antibody immune response to amezosvatein continues to be non-inferior to Shingrix

Read the original here:
Curevo Announces Positive Updated Phase 2 Data for Amezosvatein Shingles Vaccine

Related Posts